11.95

9.03% +0.99

GH Research PLC (GHRS)

Overview News Price History Option Chain Discussions Forecast

GH Research PLC stock is currently priced at $11.95, with a 24-hour trading volume of 117.07K. It has seen a +9.03% increased in the last 24 hours and a +7.85% rose in the past month. The chart indicates a potential bullish trend, as the stock is above the $11.00 pivot point. If it approaches the $11.71 resistance level, significant changes may occur.

Previous Close:

$10.96

Open:

$11.105

24h Volume:

117.07K

Market Cap:

$621.74M

Revenue:

Net Income/Loss:

$-35.59M

P/E Ratio:

-17.39

EPS:

-0.687

Net Cash Flow:

$-33.44M

1W Performance:

+7.85%

1M Performance:

+7.85%

6M Performance:

+69.26%

1Y Performance:

+32.78%

1D Range:

$10.97

$12.38

52W Range:

$5.05

$14.64

GH Research PLC Stock (GHRS) Company Profile

Name

GH Research PLC

Sector

Healthcare (1189)

Industry

Biotechnology (685)

Phone

353 1 437 8443

Address

28 Baggot Street Lower, Dublin 2, Dublin

Employee

Twitter

Next Earnings Date

Latest SEC Filings

GHRS's Discussions on Twitter

GH Research PLC Stock (GHRS) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
Aug-16-22	Initiated	H.C. Wainwright	Buy
Jun-16-22	Initiated	ROTH Capital	Buy

GH Research PLC Stock (GHRS) Latest News

How Much Upside is Left in GH Research PLC (GHRS)? Wall Street Analysts Think 321.28%

Zacks Investment Research

GH Research Reports Full Year 2023 Financial Results and Provides Business Updates

GlobeNewswire Inc.

GH Research Announces Grant of European Patent Covering all Mebufotenin (5-MeO-DMT) and Mebufotenin Salt Products For Use in the Treatment of Major Depressive Disorder and Treatment-Resistant Depression

GlobeNewswire Inc.

Can GH Research PLC (GHRS) Climb 488.72% to Reach the Level Wall Street Analysts Expect?

Zacks Investment Research

Why Urban Outfitters Shares Are Trading Lower By Around 10%? Here Are Other Stocks Moving In Wednesday's Mid-Day Session

Benzinga

HP, Iridium Communications And Other Big Stocks Moving Higher On Wednesday

Benzinga

GH Research PLC Stock (GHRS) Financials Data

GH Research PLC (GHRS) Net Income 2024

GHRS net income (TTM) was -$35.59 million for the quarter ending December 31, 2023, a -58.47% decrease year-over-year.

GH Research PLC (GHRS) Cash Flow 2024

GHRS recorded a free cash flow (TTM) of -$33.44 million for the quarter ending December 31, 2023, a -27.30% decrease year-over-year.

GH Research PLC (GHRS) Earnings per Share 2024

GHRS earnings per share (TTM) was -$0.68 for the quarter ending December 31, 2023, a -57.77% decline year-over-year.

GH Research PLC, a clinical-stage biopharmaceutical company, engages in developing various therapies for the treatment of psychiatric and neurological disorders. The company focuses on developing 5-Methoxy-N,N-Dimethyltryptamine (5-MeO-DMT) therapies for the treatment of patients with treatment-resistant depression (TRD). Its lead program is GH001, an inhalable 5-MeO-DMT product candidate that is being investigated in the Phase 2 part of an ongoing Phase 1/2 clinical trial in patients with TRD. The company also develops GH002, an injectable 5-MeO-DMT product candidate that is in preclinical development trials with a focus on psychiatric and neurological disorders. GH Research PLC was founded in 2018 and is based in Dublin, Ireland.